Eli Lilly LLY signed a definitive agreement to acquire Verve Therapeutics VERV for a total deal value of nearly $1.3 billion.

Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives ...

Secretary of Agriculture Brooke Rollins on Wednesday announced a plan to enhance the agency's ability to detect, control and ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Global shares are mostly higher and oil prices have slipped as investors await a decision on interest rates by the Federal Reserve. The inflation-fighters at the Fed are expected to ...

With plenty of GLP-1 money to spend, Eli Lilly and Co. is buying Verve Therapeutics Inc. and its gene-editing program for ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Diaylsis-technology maker Fresenius Medical Care could end up benefiting from blockbuster obesity drugs, according to its chief executive, contrary to concerns that such treatments could deplete ...

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Verve Therapeutics VERV in the last three months. The table below provides a snapshot of their ...

Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company ...